The FDA issued a notice today warning that its recall of the Vascular Solutions Langston dual lumen catheter is identified as Class I, the most serious kind of recall. Vascular Solutions, a Teleflex (NYSE:TFX) subsidiary, designed the Langston dual lumen catheter for the rapid delivery of dye into blood vessels during medical imaging tests, allowing physicians to […]
Medtech M&A: The 10 biggest deals so far in 2017
Over the past several years, the healthcare industry as a whole has experienced an abundance of mergers and acquisitions – major players are buying up their peers in deals ranging from millions to billions. The trend is continuing, and the healthcare playing field continues to be shaped by these mega-transactions. For the medical device industry, […]
Teleflex says Venture Cath recall is FDA Class I
Teleflex (NYSE:TFX) subsidiary Vascular Solutions today updated on a voluntary recall of its Venture Catheters over issues with excess material on the devices, saying that the FDA labeled it as a Class I recall, it’s most serious designation for recalls. Class I recall designations, the FDA’s most serious classification of recall, are used when there is a […]
Teleflex’s Vascular Solutions recalls Venture catheters
Teleflex (NYSE:TFX) subsidiary Vascular Solutions is recalling its Venture line of catheters after discovering a manufacturing defect that could cause embolisms. “After an internal investigation, VSI has concluded there is a potential for excess material used to manufacture the catheter to be present within the inner lumen of the distal catheter tip. It is possible that the excess […]
Failure to thrive: Lessons learned from medtech innovations that missed the mark
Some of the medical device industry’s most heralded disruptors wound up being its biggest failures. Here’s what we can learn from their mistakes. Fink Densford, Associate Editor No one in medtech sets out to fail. No one invests in building a device believing that, despite years of research and development, it won’t make the cut. […]
Teleflex wins FDA nod for Trapliner cath, sees shares rise on Street-topping Q4, FY2016 earnings
Teleflex (NYSE:TFX) today said it won FDA 510(k) clearance for its TrapLine Catheter and saw shares tick up upon the release of 4th quarter and full fiscal year 2016 earnings that beat expectations on The Street. The company’s TrapLine catheter was developed by Vascular Solutions, which Teleflex officially acquired last week. The TrapLiner is intended for use in conjunction with guide […]
Vascular Solutions shareholders approve $1B Teleflex takeover
The $1 billion takeover of Vascular Solutions (NSDQ:VASC) by Teleflex (NYSE:TFX) is slated to close today after Vascular Solutions shareholders yesterday approved the deal. The $56-per-share sale brings a portfolio of more than 90 coronary and peripheral vascular devices under the Teleflex umbrella. When the deal was announced last December, Teleflex CEO Benson Smith said that part of the acquisition’s […]
Vascular Solutions shareholders sue to block $1B Teleflex buyout
A group of Vascular Solutions (NSDQ:VASC) shareholders last week sued to block a $1 billion buyout by Teleflex (NYSE:TFX), arguing that the deal undervalues Vascular Solutions and locks out any competing bids. The purported class action, filed Jan. 27 in the U.S. District Court for Minnesota, alleges that the $56-per-share Teleflex deal is an “inadequate consideration” for Vascular Solutions. “Among […]
How Howard Root guided Vascular Solutions to a $1B buyout – and beat federal prosecutors
Fresh from a huge legal win over the U.S. Justice Dept., Howard Root guided Vascular Solutions to a $1 billion buyout. Here’s what he learned about leadership along the way. It’s been a banner year in many ways for Vascular Solutions. Apart from top-line growth of some 17%, the company was named to the Forbes […]
Teleflex puts up $1B for Vascular Solutions
Teleflex (NYSE:TFX) said today it will pay approximately $1 billion to acquire Vascular Solutions (NSDQ:VASC). Through the deal, Teleflex will pick up all outstanding shares of Vascular Solutions at $56 per share, in cash. Boards of both companies have approved the deal, which is expected to close during the 1st half of 2017. “We are extremely excited […]
Legal win leaves Vascular Solutions CEO Root weary of the corner office
After being acquitted of federal felony charges for off-label marketing and a prosecution that spanned 5 years, Vascular Solutions (NSDQ:VASC) CEO Howard Root said he’s still recovering from the strain of battling federal prosecutors. TJSmith, a lawyer, said if it wasn’t for his previous life in the field of law he would have cracked under the pressure […]
- 1
- 2
- 3
- …
- 6
- Next Page »
